Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
A Multi-Center, Open-Label (OL), Active-Controlled, Dose-Titration Study Evaluating the Safety, Efficacy and PK of Oxybutynin Transdermal Systems in the Treatment of Detrusor Overactivity in Pediatric Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Watson Investigational Site
-
-
California
-
Orange County, California, United States
- Watson Investigational Site
-
San Diego, California, United States
- Watson Investigational Site
-
-
Colorado
-
Denver, Colorado, United States
- Watson Investigational Site
-
-
District of Columbia
-
Washington DC, District of Columbia, United States
- Watson Investigational Site
-
-
Michigan
-
Detroit, Michigan, United States
- Watson Investigational Site
-
-
Minnesota
-
Mineapolis, Minnesota, United States
- Watson Investigational Site
-
-
Mississippi
-
Jackson, Mississippi, United States
- Watson Investigational Site
-
-
Missouri
-
Kansas City, Missouri, United States
- Watson Investigational Site
-
St. Louis, Missouri, United States
- Watson Investigational Site
-
-
New Jersey
-
Voorhees, New Jersey, United States
- Watson Investigational Site
-
-
New York
-
Albany, New York, United States
- Watson Investigational Site
-
Buffalo, New York, United States
- Watson Investigational Site
-
Poughkeepsie, New York, United States
- Watson Investigational Site
-
-
North Carolina
-
Ashville, North Carolina, United States
- Watson Investigational Site
-
Durham, North Carolina, United States
- Watson Investigational Site
-
-
Ohio
-
Columbus, Ohio, United States
- Watson Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Watson Investigational Site
-
-
Pennsylvania
-
Hershy, Pennsylvania, United States
- Watson Investigational Site
-
-
Texas
-
Dallas, Texas, United States
- Watson Investigational Site
-
Houston, Texas, United States
- Watson Investigational Site
-
Plano, Texas, United States
- Watson Investigational Site
-
-
Utah
-
Salt Lake City, Utah, United States
- Watson Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pediatric patient with a diagnosis of detrusor overactivity associated with a neurological condition;
- Use clean intermittent catheterization
- On stable dose of oral oxybutynin before participation
Exclusion Criteria:
- Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency
- Have any medical condition that precludes their participation in the study or may confound the outcome of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oxybutynin Transdermal System
Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
|
1.3, 2.6, 3.9 mg/day transdermal
Other Names:
5 to 15 mg/day immediate release or extended release tablets, or syrup
Other Names:
|
|
Active Comparator: Oral oxybutynin
5 to 15 mg/day immediate release or extended release tablets, or syrup
|
1.3, 2.6, 3.9 mg/day transdermal
Other Names:
5 to 15 mg/day immediate release or extended release tablets, or syrup
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Catheterization Urine Volume
Time Frame: 14 weeks
|
Change from baseline in average volume of urine collected by catheterization
|
14 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Catheterizations Without Leakage
Time Frame: 14 weeks
|
Percentage of catherizations without leakage
|
14 weeks
|
|
Urine Volume After First Awakening
Time Frame: 14 weeks
|
Change from baseline in average volume of urine collected after first morning awakening
|
14 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Gary Hoel, RPh, PhD, Watson Laboratories, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Reflex, Abnormal
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Anti-Infective Agents, Urinary
- Renal Agents
- Oxybutynin
- Mandelic Acids
Other Study ID Numbers
Other Study ID Numbers
- O03010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.